Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q4 Results Preview: Shire, Bayer, Merck KGaA

Executive Summary

Potential upheavals in the hemophilia market bring uncertainty for Shire and Bayer, with executives likely to be quizzed on how they can retain market share during upcoming Q4 results calls. Scrip’s final earnings preview highlights the key challenges for large companies reporting at the tail-end of the earnings season.

Advertisement

Related Content

Hemophilia Community Not 'Choosing A Side' In Hemlibra Litigation
Better Together: BioCryst, Idera Merge To Improve Rare Disease Position
Allergan, Shire Battle In Dry Eye As Generics Advance
Forty Seven's IO Antibody Attracts Two Big Pharma Partners
Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
Big Pharma Set To Compete For German Merck's Consumer Health Unit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100324

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel